Medical News

RSS

Attitudinal beliefs feed negative schizophrenia symptoms

Dysfunctional attitudes and low self-efficacy are associated with poorer functioning in patients with early schizophrenia, and this relationship is partly mediated by negative symptoms, shows research.

26 Feb 2014

Residual symptoms linked to poor functioning in euthymic bipolar disorder

Residual symptoms are associated with functional impairment in euthymic individuals with bipolar disorder, a large observational study has shown.

26 Feb 2014

Report calls for better palliative and EOL care for patients that relapse following transplant

Haematological disorders of the blood and bone marrow, such as leukaemia, are commonly treated with a bone marrow transplant. However relapse is common and often leads to treatment failure and death.

26 Feb 2014

Griffith Health's Heidi Muenchberger among the recipients of 2014 Australian Fulbright Scholarship

How a building can improve health and healing after injury or illness is the focus of a study by Associate Professor Heidi Muenchberger, a recently announced recipient of the 2014 Australian-American Fulbright Commission Scholarships.

26 Feb 2014

Viewpoints: Finding a plan for 'tinkering with DNA'; fact-checking claims of ACA losses; pediatricians' fears of retail clinics

The manipulation of human genes could lead to profound advances in our ability to cure or prevent terrible diseases. But in some cases, it might also mean introducing genetic material that could be passed from one generation to the next, changing the human gene pool in a manner that could inadvertently harm peoples' health.

26 Feb 2014

Prothelia and University of Nevada, Reno enter into agreements with Alexion for development of Laminin-111

Prothelia Incorporated (Prothelia) and University of Nevada, Reno announce that they have entered into strategic agreements with Alexion for the development of Laminin-111, a patented experimental protein replacement therapy for merosin-deficient congenital muscular dystrophy (MDC1A), a life-threatening, ultra-rare disease caused by a genetic deficiency of the Laminin-211 protein.

26 Feb 2014

Study: Patients more likely to die in hospitals when cared for by nurses with heavy workloads

Patients are more likely to die after common surgical procedures when they are cared for in hospitals with heavier nurse workloads and fewer nurses with bachelor's degrees, concludes the largest investigation of nursing and hospital outcomes in Europe to date, published in The Lancet.

26 Feb 2014

Study highlights the importance of personalized medicine for treating cancer

If a driver is traveling to New York City, I-95 might be their route of choice. But they could also take I-78, I-87 or any number of alternate routes. Most cancers begin similarly, with many possible routes to the same disease. A new study found evidence that assessing the route to cancer on a case-by-case basis might make more sense than basing a patient's cancer treatment on commonly disrupted genes and pathways.

26 Feb 2014

Just who's exempt from the individual mandate, and how will the IRS enforce it?

One of the most debated parts of the health care law is the requirement that most Americans buy insurance starting this year. … But it's not clear that the IRS will deploy much in the way of resources to aggressively search for individuals who don't get coverage this first year (Adams, 2/24).

26 Feb 2014

ViroXis signs agreement with global pharmaceutical for marketing of OTC sandalwood oil-containing product

ViroXis Corporation is pleased to report the execution of an exclusive license agreement with a global pharmaceutical company for the marketing of an over-the-counter (OTC) sandalwood oil-containing product.

26 Feb 2014

First Edition: February 26, 2014

Today's headlines include reports that, according to the Obama administration, insurance sign-ups under the health law have hit 4 million.

26 Feb 2014

Protein M: an interview with Rajesh Grover, PhD, senior staff scientist, Lerner laboratory, TSRI

Protein M is a cell surface protein from Mycoplasma Genitalium that binds to all human antibodies.

26 Feb 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

Fred Hutchinson, SCCA researchers receive Seattle Business Magazine's 2014 Leaders in Health Care Awards

Researchers at Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance (SCCA) were recognized in several categories of Seattle Business Magazine's 2014 Leaders in Health Care Awards, including the publication's Lifetime Achievement Award, given to Frederick R. Appelbaum, M.D., executive vice president and deputy director of Fred Hutch and president of SCCA.

26 Feb 2014

Santalis Pharmaceuticals partners with TFS for marketing of OTC dermatology products

Santalis Pharmaceuticals Inc., a joint venture with TFS Corporation Ltd., of Australia (ASX: TFC) is pleased to report the execution of an exclusive license agreement with a global pharmaceutical company for the marketing of a number of over-the-counter (OTC) dermatology products containing TFS' sustainably cultivated, pharmaceutical-grade East Indian Sandalwood Oil (EISO).

26 Feb 2014

Second common type of breast cancer appears to be good candidate for personalized treatment approach

The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to a multidisciplinary team led by University of Pittsburgh Cancer Institute (UPCI) scientists.

26 Feb 2014

Nurses in emergency care must be trained to recognise symptoms of meningococcal septicaemia

Nurses working in emergency care environments must be trained to recognise the atypical signs and symptoms of meningococcal septicaemia.

26 Feb 2014

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).

26 Feb 2014

K-PAX Pharmaceuticals works with Stanford University to identify effective treatment for chronic fatigue

K-PAX Pharmaceuticals is working with Stanford University and several other leading research institutions to perform a Phase II double-blind, placebo-controlled trial to evaluate the safety and efficacy of a currently available FDA-approved medication concurrently administered with a novel mitochondrial support product in order to identify a safe and effective treatment for the chronic fatigue and decreased alertness (i.e. brain fog) that commonly afflicts people with CFS.

26 Feb 2014

Ventana to convene Tissue Diagnostics Patient Safety Advisory Board to improve patient safety in labs

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it will convene a Tissue Diagnostics Patient Safety Advisory Board on February 27 at its headquarters in Tucson, Arizona.

26 Feb 2014

Medical News

Attitudinal beliefs feed negative schizophrenia symptoms

Residual symptoms linked to poor functioning in euthymic bipolar disorder

Report calls for better palliative and EOL care for patients that relapse following transplant

Griffith Health's Heidi Muenchberger among the recipients of 2014 Australian Fulbright Scholarship

Viewpoints: Finding a plan for 'tinkering with DNA'; fact-checking claims of ACA losses; pediatricians' fears of retail clinics

Prothelia and University of Nevada, Reno enter into agreements with Alexion for development of Laminin-111

Study: Patients more likely to die in hospitals when cared for by nurses with heavy workloads

Study highlights the importance of personalized medicine for treating cancer

Just who's exempt from the individual mandate, and how will the IRS enforce it?

ViroXis signs agreement with global pharmaceutical for marketing of OTC sandalwood oil-containing product

First Edition: February 26, 2014

Protein M: an interview with Rajesh Grover, PhD, senior staff scientist, Lerner laboratory, TSRI

FDA approves KALYDECO for people with cystic fibrosis

Fred Hutchinson, SCCA researchers receive Seattle Business Magazine's 2014 Leaders in Health Care Awards

Santalis Pharmaceuticals partners with TFS for marketing of OTC dermatology products

Second common type of breast cancer appears to be good candidate for personalized treatment approach

Nurses in emergency care must be trained to recognise symptoms of meningococcal septicaemia

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

K-PAX Pharmaceuticals works with Stanford University to identify effective treatment for chronic fatigue

Ventana to convene Tissue Diagnostics Patient Safety Advisory Board to improve patient safety in labs

Directed enzyme evolution and the Nobel Prize: Making enzymes evolve in the lab

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Latest News